If you are not able to view this e-mail properly, please click here to view it online
World Pharma Today Maqazine
World Pharma Today Linkedin Page World Pharma Today Facebook Page World Pharma Today Twitter Page Weekly Newsletter
Click here to subscribe to our Magazine
World Forum For Medicine
Top Latest Press Releases
The Great Hall of China: double digit growth at CPhI China

The Great Hall of China: double digit growth at CPhI China

P-MEC China, CPHI china , UBM Sinoexpo,Chinese pharmaceutical market development,Asia largest pharma event CPhI and P-MEC China, organised by UBM EMEA, UBM Sinoexpo and China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE)...


Aridis Is Enrolling Patients in Pivotal Trial of Its Antibiotic-resistant Pneumonia Therapy Aerucin

Aridis Pharmaceuticals, Inc announced that it is now actively enrolling patients in a global pivotal study of Aerucin, the Company broadly reactive monoclonal antibody being developed to treat acute pneumonia caused by Gram-negative bacteria Pseudomonas...


CRL from the FDA for latanoprostene bunod ophthalmic solution , received by Valeant Pharmaceuticals

Valeant Pharmaceuticals International, Inc announced it has received a CRL from the U.S. FDA regarding the NDA for latanoprostene bunod ophthalmic solution, 0.024%, an investigative intraocular pressure lowering single-agent eye drop for patients with open angle...

InDex Pharmaceuticals receives ORD for pediatric ulcerative colitis in the US

InDex Pharmaceuticals receives orphan-drug designation for pediatric ulcerative colitis in the US

InDex Pharmaceuticals Holding AB announced that the US FDA has granted orphan-drug designation for the drug candidate cobitolimod for treatment of ulcerative colitis in pediatric patients.


Biovista expands Project Prodigy collaborations in personalized medicine

Biovista announced that it is collaborating with HPE to advance Biovista Project Prodigy Big Data AI healthcare platform applied in the personalized medicine vertical.


Randomization In Phase 2/3 Trial In Spinocerebellar Ataxia Completed By Biohaven

Biohaven announced that it has commenced dosing of all 141 randomized patients with spinocerebellar ataxia (SCA) in its Phase 2/3 trial of trigriluzole (previously known as BHV-4157).


For Advertising Queries:

Please e-mail : kathryn@worldpharmatoday.com
call to: + 91 88268 49084

If you like to receive our latest Media Pack 2017 / Editorial Calender please click here


For the latest visit: www.worldpharmatoday.com

World Pharma Today